Concurrent radiotherapy with S-1 plus cisplatin versus concurrent radiotherapy with cisplatin alone for the treatment of locally advanced cervical carcinoma: a pilot randomised controlled trial

• Z. Li ^[1] ; W. Mao ^[1] ; N. Lin ^[1] ; S. Han ^[1]
  1. [1] Harbin Medical University

     Harbin Medical University

     China

     
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 18, Nº. 4 (April 2016), 2016, págs. 413-417
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Background In the present study, we compared the efficacy and safety of concurrent radiotherapy with S-1 plus cisplatin (CRSC) versus concurrent radiotherapy with cisplatin alone (CRC) for the treatment of advanced cervical carcinoma (ACC).

    Methods Between February 2006 and January 2009, 72 eligible patients with ACC were included and randomly divided into two groups. Thirty-six patients received CRSC with radiotherapy (60 Gy/30 fractions over 6 weeks) beginning on day 1, S-1 (according to body surface area) for 28 days repeated every 6 weeks, and cisplatin (50 mg/m2, intravenously on day 1) every 4 weeks for two cycles. The other 36 received CRC at the same cisplatin and radiotherapy dosage as for CRSC. The primary outcome was overall survival, whereas the secondary outcomes included progression-free survival and toxicity.

    Results The median overall survival was 75 months (range 4–86 months) for the CRSC group and 66 months (range 3–87 months) for the CRC group (P = 0.039). The median corresponding progression-free survival was 66 months (range 3–75 months) and 58 months (range 3–71 months), respectively (P = 0.042). The toxicity profile was similar in both the groups.

    Conclusion Our results suggested that CRSC might be more effective than CRC in patients with ACC with acceptable toxicity.